Skip to content
Skip to navigation
Skip to footer

Press Releases

View global media contacts

Latest

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population
28 March 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19
24 March 2022
Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer
24 March 2022
AstraZeneca launches global R&D Postdoctoral Challenge to accelerate scientific discovery and diversity
17 March 2022
AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomiris
17 March 2022
AstraZeneca’s antibody combination, Evusheld▼ (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19
17 March 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer
16 March 2022
Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps
14 March 2022
Lynparza approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
11 March 2022
Nirsevimab significantly protected infants against RSV disease in Phase III MELODY trial
3 March 2022

previous
1
2
3
4
5
6
28
next

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2020 so you should be able to find just what you are looking for.

Explore archive